Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fentanyl sublingual tablet
- Development stage
- Phase 3
- Lead developer
- Orexo
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
KW-2246 is a rapidly-disintegrating, sublingual formulation of fentanyl developed for the treatment of breakthrough pain in cancer patients who are already receiving opioid analgesics for chronic pain. It acts as an agonist at the mu-opioid receptor (OPRM), providing prompt and potent analgesia due to rapid absorption via the oral mucosa. The drug was developed by Kyowa Hakko Kirin under license from Orexo AB and is marketed under the brand name Abstral in several regions outside Japan. In Japan, it underwent clinical trials and regulatory review for use as rescue medication in breakthrough cancer pain[1][2][5][7].
- Brand names
- Abstral
- Other names
- fentanyl sublingual tabletrapidly-disintegrating sublingual fentanylAbstral
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on fentanyl sublingual tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fentanyl sublingual tablet.